Vertex Pharmaceuticals Gets FDA OK for Sickle Cell Disease Treatment in Young Children
By Elias Schisgall
The Food and Drug Administration approved the use of Vertex Pharmaceuticals's sickle cell disease treatment, Casgevy, for patients as young as two years old.
The agency said Wednesday that it issued a supplemental approval for the drug, known generically as exagamglogene autotemcel, for patients between the ages of two and 11. It was previously approved to treat patients 12 years of age and older.
Casgevy is approved to treat patients with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β thalassemia, another blood disorder. The FDA said Casgevy is the first gene therapy approved for sickle cell disease patients as young as two.
The approval is the eighth selected for the FDA Commission's National Priority Voucherpilot program, the agency said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
July 01, 2026 19:21 ET (23:21 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States